跳至主要内容
临床试验/PACTR202408671139802
PACTR202408671139802招募中3 期

A randomized controlled study of effectiveness, maternal and perinatal outcomes in the use of labetalol versus hydralazine in the management of severe pre-eclampsia in Ahmadu Bello university teaching hospital, Zaria.

Sakina Ghazali0 个研究点目标入组 100 人开始时间: 2023年12月17日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
Female

入选标准

  • 1.Severe hypertension (systolic blood pressure of 160mmHg or more and /or diastolic blood pressure of 110mmHg or more) and Proteinuria of 2+ or more as measured by dipstick in a catheter specimen urine sample.
  • 2.Pregnancy = 28 weeks gestation.
  • 3.Singleton pregnancy.
  • 4.Live fetus with normal fetal heart rate.

排除标准

  • 1.Medicaldisorderslikeasthma,cardiacfailure,heartblock, cardiac arrhythmias.
  • 2.Contraindication or known allergy to hydralazine or labetalol neurological disease.
  • 3.Fetal congenital abnormality.
  • 4.Women who refuse consent.
  • 5.Referrals already on anti-hypertensive.

研究者

发起方
Sakina Ghazali

相似试验